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ABSTRACT
Although nucleic acid tests (NATs) for human immunodeficiency virus (HIV) exhibit
many advantages, such as early detection and viral load quantification, over
immunological assays, their widespread use is limited by their demand for highlevel infrastructure, sophisticated equipment, and advanced staff competence.
Furthermore, when quantifying viral loads of patients, it has been reported that
these assays can underestimate viral quantities by 22- to 100-fold due to primertemplate mismatches in more divergent HIV subtypes. Therefore, we have
developed a cost-effective and sequence-independent assay for the detection and
quantification of HIV utilizing a modified nucleic acid sequence-based amplification
(NASBA) protocol coupled to an electrochemical DNA biosensor. The modified
NASBA reaction involves the addition of a 22-nucleotide tag between the T7 RNA
Polymerase Promoter and the hybridizing region of the reverse primer. As a result,
this tag will be placed at the 5' end of each amplicon regardless of the target
sequence. We then designed the DNA sensor to hybridize to this segment of the
amplicon specifically. Therefore, hybridization, and subsequently, detection, is
dependent only on the presence of this tag and not the viral RNA sequence itself. As
a result, the issue of underestimating viral loads is eliminated as multiple primers
can be used in one reaction without having to use multiple sensors. The use of an
isothermal NASBA technique and a reusable gold-disc electrode for the sensor helps
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drive down the cost of the assay by eliminating the need for thermocyclers and
fluorometers used by conventional NATs.
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INTRODUCTION
Human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2) are both species
of human lentivirus and are the causing agents of acquired immunodeficiency
syndrome (AIDS).1 HIV can be found in the blood, semen, pre-seminal fluid, vaginal
fluid, rectal fluid, and breast milk of infected individuals and can be transmitted via
contact of any of these fluids with a mucous membrane, damaged tissue, or by direct
injection into the bloodstream. Although less common, it is also possible that a mother
can pass HIV to her child during pregnancy, childbirth, and breastfeeding.2 Upon two
to four weeks of initial infection with HIV, an individual may experience nonspecific
flu-like symptoms; however, none of these symptoms are unique to HIV infection, and
not all infected patients experience initial symptoms. When left untreated, HIV
infection progresses to AIDS, marked by severe damage to the immune system,
specifically a loss of the majority of the infected individual's CD4 T-cells and,
consequently, the appearance of opportunistic infections. If the individual is still left
untreated, death will typically occur approximately three years after the development
of AIDS.3
Since the start of the AIDS epidemic, according to the United Nations Joint
Programme on HIV/AIDS (UNAIDS), a total of 75.7 million people have been infected
with HIV, and of which 32.7 million have died due to AIDS-related illnesses.4 In 2016,
UNAIDS defined several targets for HIV testing and treatment to be achieved by
2020 to end the AIDS epidemic by 2030. Such milestones include the reduction of the
1

yearly infection rate to 500,000 new infections per year, the reduction of yearly AIDSrelated deaths to 500,000 deaths per year, and the 90-90-90 goal, requiring that 90%
of HIV-infected individuals be aware of their status, of which 90% are receiving
treatment, and of which 90% have undetectable viral loads.5 We have now passed the
goal year, and, based on data from 2019, we are not projected to meet any of these
milestones.6 Although the targets were reached in a handful of countries, most lowand middle-income countries continue to fall behind the global goal in part due to
decreases in funding for implementation of widespread diagnostic and treatment
efforts and income disparities.6 To achieve these goals, extensive HIV testing is
required, not only to diagnose new cases but in order to monitor the viral loads of
those living with HIV.6, 7 While HIV testing, counseling, and treatment services have
been greatly expanded in efforts to end the AIDS pandemic, decreases in funding and
the economic crises imposed by the COVID-19 pandemic, threaten to undermine the
progress made thus far, particularly in low- and middle-income countries.6 Therefore,
there is a greatly increased need for affordable quantitative HIV diagnostics to be
implemented in this area.
The Evolution of HIV and Its Subtypes
Although HIV-1 and HIV-2 are causative agents of AIDS, their origin and,
consequently, their infectivity and virulence vary. Both viruses evolved due to a
transmission of a strain of simian immunodeficiency virus (SIV) to humans. Several
distinct transmission events of either chimpanzee or gorilla SIV—SIVcpz and SIVgor,
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respectively—led to the various HIV-1 groups termed as M, N, O, and P. Each group
originates from a single transmission event of SIV—either SIVcpz or SIVgor—from
an ape to a human. Group M, a result of cross-species transmission of SIVcpz to
humans, was the first to be discovered and is identified as the group of HIV that
caused the AIDS pandemic. Group M can also be subdivided into subtypes A-D, F-H,
J, K, and several circulating recombinant forms. Groups N, O, and P were discovered
later and are much less common, with group O making up less than 1% of HIV-1
infections, group N having been identified in only 13 individuals, and group P in only
one individual.8
Similarly, eight different lineages of HIV-2, termed A-H, have been identified, all of
which originated with a strain of SIV that infects sooty mangabey monkeys
(SIVsmm).8 As SIVsmm is a significantly different virus from both SIVcpz and
SIVgor,8 it is unsurprising that HIV-1 and HIV-2 are also genetically distant, with
only a 55% sequence identity.9 Consequently, the viral properties of both are also
vastly different. HIV-2 remains prominent only in West Africa, has lower
transmission rates, lower viral loads than HIV-1, and most individuals who become
infected with HIV-2 do not develop AIDS.8 Furthermore, due to the lower
transmission rates of HIV-2, the prevalence of this species of HIV continues to decline
as it is replaced by infections with HIV-1, even in West African countries.8

3

Structure and Life Cycle of HIV
The HIV virion is comprised of two copies of a positive-sense single-stranded RNA
(ssRNA) genome. Each copy of the ssRNA genome is also associated with a protein
complex comprised of a chain of nucleocapsid protein (p7), an integrase enzyme (p31),
and a reverse transcriptase enzyme (p51/p66).10 Each complex is enclosed in a viral
capsid composed of p24 proteins (Figure 1). The capsid core is then enclosed by a
matrix composed of p17 monomers, which also houses several copies of the HIV
protease enzyme. Anchored to the membrane are spikes, termed Env proteins. Each
spike is a trimer of gp41-gp120 heterodimers, known as the transmembrane envelope
protein and the surface envelope protein, respectively. 10, 11
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Figure 1. A schematic diagram of an HIV virion.
Source: Freed, E. O., 1998. Used with permission.

Infection is initiated when the gp120 protein on an HIV virion binds to a CD4 receptor
on CD4-expressing cells (CD4+), most notably CD4 T lymphocytes (Figure 2A).10, 12
The binding of CD4 induces a conformational change in gp120, which exposes a
coreceptor binding site (Figure 2B). The binding of a chemokine coreceptor (Figure
2C), typically CXCR4 or CCR5, to gp120 further induces a series of conformational
changes, allowing for the extension of gp41 and the insertion of its fusion peptide,
which brings the membrane of virion in close proximity to the membrane of the
5

potential host cell (Figure 2D). Refolding of the gp41 protein into a stable six-helix
bundle is the last stage of this process and fuses the membrane of the virion to that
of the cell (Figure 2E).11, 13

Figure 2. A scheme showing the process of CD4 and coreceptor binding to gp120 followed by
membrane fusion.
Source: Alkhatib G., et al., 2009. Used with permission.

Upon fusion, the viral matrix and its contents are released into the cytoplasm of the
cell. As this occurs, reverse transcription of the ssRNA genome into double-stranded
DNA (dsDNA) begins, and the viral capsid begins to degrade (Figure 3).10, 14, 15 As the
capsid degrades, reverse transcription of the two ssRNA genome copies into doublestranded DNA begins.15,

16

The dsDNA, nucleocapsid, integrase, reverse
6

transcriptase, and viral protein R (VpR) are retained in a preintegration complex,
then transported to the cell's nucleus.17-19 Inside the nucleus, integrase inserts the
viral dsDNA genomes into the host cell's DNA. The integrated DNA, known as the
provirus, servers as a template for the transcription of viral proteins.20 During viral
replication, HIV envelope spike proteins are placed on the host cell's membrane. After
assembly of the RNA, polyprotein precursors, and enzymes, the immature virion may
bud off with the spikes attached.10, 21, 22

7

Figure 3. An overview of the HIV life cycle.
Source: Freed, E. O., 1998. Used with permission.

Shortly after budding, the protease enzyme begins to cleave the polyprotein
precursors into functional enzymes, and a mature virion is formed after the assembly
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of the core capsid.22, 23 The mature virus may now repeat this cycle of infection in
another host cell.10
Stages of HIV Infection
HIV viremia is defined by an eclipse phase followed by six stages, termed the Fiebig
stages, determined by the presence or absence of specific HIV biomarkers.24 The
duration of each stage is variable in each case and depends on several factors, such
as the genetics of the virus and the genetics and immunocompetence of the host
individual.25 Several techniques exist for the detection of HIV in the blood, each
dependent on an individual biomarker, and thus, each valid for use at a different
stage of HIV infection.24, 25
Immediately after HIV infection, an infected individual will enter the Acute HIV
Infection (AHI) phase of the disease. This period begins when HIV infection is
established, but before seroconversion occurs, and corresponds to Fiebig stages I and
II.24 During both the eclipse phase and stage I of infection, HIV RNA is the only
biomarker present; however, in the eclipse phase, HIV RNA is present at low
concentrations in the blood, not detectable by most RNA quantification methods
(Figure 4).26 When the viral load of a patient reaches 50 copies/mL of blood, the RNA
is now detectable by most quantification assays, and the infection has progressed to
stage I, which occurs, on average, eleven days post-infection.26 The viral load, or RNA
concentration, continues to increase throughout stage I and will begin to plateau at
the end of stage II at approximately 106 copies/mL in the blood.24, 26
9

During stage II, the p24 antigen, a protein found in the HIV viral capsid, 10 becomes
detectable in the blood, which, in turn, triggers seroconversion.24 As seroconversion
occurs, the number of anti-HIV antibodies will increase, and free-p24 levels will
decrease as it binds to the antibodies. By the end of stage III, p24 levels are close to
zero and may no longer be detectable.24 Therefore, an assay that would test solely for
the p24 antigen would suffer from a window closure, meaning that patients who
receive the test post seroconversion would test negative for HIV.24, 25 Consequently, a
combination, or fourth-generation, test has been developed that tests for both the p24
antigen and HIV antibodies to overcome the window closure.25 Assays that test solely
for HIV antibodies are termed third-generation tests and become valid for use after
stage IV or V, depending on test sensitivity.24, 27 Throughout stages III and IV, as the
immune system begins to suppress viral replication, the RNA levels will also decline
and plateau once more at 104 copies/mL. At this point, without medical intervention,
the concentration of HIV RNA will remain constant throughout the lifetime of the
host.24 Stages V and VI are marked by a positive Western Blot test and a positive p31
antigen test, respectively.24, 26 However, both tests, due to lack of specificity, have
been rendered obsolete or for supplemental use only.25

10

Figure 4. Fiebig stages of HIV infection are characterized by several biomarkers and changes in viral
RNA concentration in plasma.
Stage I begins with the detection of viral RNA (v RNA+). Stage II begins slightly before
seroconversion and is marked by the ability to detect the p24 antigen (p24Ag+). A positive enzymelinked immunosorbent assay (ELISA+), which tests for anti-HIV antibodies, marks the beginning of
Stage III. Western blot (now obsolete),25 which tests for nine HIV-specific proteins, may be positive
at Stage IV (Western blot +/-) but may take until Stage V to show a positive result without a p31
band (Western blot + p31-). At Stage IV, Western blot is positive with a p31 band (Western + p31+).
Source: Cohen, M.S., et al., 2010. Used with permission.

Current Viral Load Assays and Their Limitations
When HIV treatment, termed antiretroviral therapy (ART), is administered to
patients, their viral loads are periodically monitored, typically every 3, 6, or 12
months, using a quantitative nucleic acid test (NAT), which measures the
11

concentration of viral RNA in patient plasma.7,

28

Periodic viral load testing allows

providers to detect possible treatment failure, either due to HIV superinfection—when an
individual already living with HIV is infected with another strain of HIV—or due to the
development of viral resistance to the ART cocktail.7, 29, 30 However, current NATs
are resource-intensive assays and require highly-trained personnel and a high degree
of infrastructure to implement, which greatly limits their use in low- and middleincome countries.7, 25 In these settings, viral load testing is often replaced by testing
CD4 cell counts. However, this method is not nearly as sensitive as a viral load assay
and can only detect treatment failure once damage to the immune system occurs due
to the increased viral replication.7 Another limitation of current quantitative NATs
is that there is no commercially available NAT assay that can accurately quantitate
all subtypes and groups of HIV-1 and HIV-2.31-35 Additionally, it has been reported
that some assays underestimate the viral loads of patients infected with certain HIV
subtypes due to a large number of primer-template mismatches.36 In regions such as
Sub-Saharan Africa, where there is a wide diversity of circulating HIV-1 subtypes, or
in West Africa, where HIV-1 subtypes are present alongside HIV-2, the lack of a
'universal' HIV quantitative assay poses a major challenge to the implementation of
viral load testing in those areas.37
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METHODOLOGY
Hypothesis
In this work, we proposed to develop a low-resource assay designed to accurately
quantitate the viral loads of patients carrying various HIV subtypes. The proposed
assay comprises two steps: amplification of HIV RNA and the subsequent detection
of the amplicons. The amplification step is accomplished using a modified nucleic acid
sequence-based amplification (NASBA) technique. Following amplification, detection
is achieved using a four-way junction (4WJ) electrochemical biosensor.
RNA Amplification
Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), also
referred to as real-time RT-PCR, is the gold standard for quantitative NAT assays,
including those for HIV.

32-35, 38

A real-time RT-PCR machine typically consists of a

thermal cycler coupled to a fluorometer—an expensive and sophisticated combination
that is not easily transported and cannot be used in the field.38 Among other factors,
these machines' requirements are a major limiting factor towards applying NATs in
a point-of-care, field, or low-resource setting.
NASBA is an alternative RNA amplification technique that offers several advantages
over RT-PCR. Most importantly, NASBA is an isothermal amplification technique
and may be performed using a water bath or incubator instead of a thermal cycler.
Furthermore, NASBA was designed to use single-stranded RNA (ssRNA) directly as
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the template for amplification and produce an ssRNA product. This product is
preferable to the dsDNA product of RT-PCR as it will not require downstream
denaturation when used with sequence-specific hybridization probes. Finally, in RTPCR, the primers used are incorporated into the final amplicon, limiting the
maximum yield of amplification, which cannot exceed the initial concentration of the
primers in the reaction. Conversely, when using NASBA, the DNA primers are not
incorporated into the ssRNA amplicon. Therefore, the final amplicon concentration
can exceed the initial concentration of primers by up to one order of magnitude.39, 40
Thus, the use of NASBA in NAT assays in place of RT-PCR brings these assays a step
closer towards applicability in low-resource settings.

14

NASBA Amplification

Figure 5. A schematic of an antisense-producing NASBA reaction, including the denaturing step.
Created with BioRender.com.

Depending on how the primers are designed, NASBA can produce either a sense or
antisense ssRNA product. The protocol typically begins with a denaturing step in
which all the reaction components, except for enzymes, are combined and heated to
65 °C (Figure 5) to denature the secondary structure of the template RNA. Although
some works suggest that the denaturing step may be skipped while retaining
successful amplification with some loss of efficiency, we did not explore this option in
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this work.40 In order to produce an antisense amplicon, the reverse primer (RP)
contains a T7 RNA Polymerase promoter at its 5’-end that is functional only when
double-stranded. The reaction is then cooled to 41 °C and remains at this temperature
until the completion of the protocol. At this temperature, RP anneals to the template
RNA, and the enzyme cocktail (avian myeloblastosis virus reverse transcriptase
(AMV-RT), T7 RNA Polymerase, and RNase H) is added. Once the enzyme cocktail is
added, AMV-RT will reverse transcribe the target ssRNA starting at the 3’-end of the
reverse primer to create an RNA:cDNA hybrid. The RNA strand of this hybrid is then
hydrolyzed by RNase H, which allows the forward primer (FP) to bind the newly
synthesized cDNA strand. Reverse transcriptase then catalyzes the FP elongation to
produce a DNA duplex with a double-stranded T7 promoter. T7 RNA Polymerase is
then able to bind to the promoter and synthesize an antisense ssRNA amplicon. The
amplicons are then used as templates to carry on the amplification with the primers
binding in reverse order, enabling exponential amplification of the amplicon.40, 41
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Amplicon Tagging

Figure 6. Schematic of the NASBA Tagging Procedure
Created with Biorender.com

One of the main objectives of this work is to propose an assay that can accurately
quantitate all subtypes of HIV. With some current assays, it has been reported that
primer-template mismatches reduce the NAT's amplification efficiency, leading to
underestimation of the viral load.36 We circumvent this problem by 'tagging' the
amplicon with an extra 22-nts sequence at the 5’-end, which can then be hybridized
to probes for subsequent detection. This is accomplished by placing the 22-nts
sequence (Table 1) between the T7 RNA Polymerase promoter and the hybridizing
17

region of RP. During amplification, all nucleotides downstream of the promoter will
be transcribed, including the tag. Thus, all amplicons produced by this modified
NASBA technique will contain the tag (Figure 6). The use of the tag as the target for
subsequent detection entails that any tagged amplicon, regardless of the sequence
downstream of the tag, will be detected by our assay. With this design, a cocktail of
primers can be used in each NASBA reaction, with each primer designed specifically
for an individual HIV subtype—or grouping of subtypes—to ensure highly efficient
amplification of all subtypes.
Electrochemical Detection and Quantitation
The development of biosensors is a highly attractive field for creating novel NATs,
especially in view of the need for more affordable diagnostic tools.42 Electrochemical
biosensors are highly sensitive, portable, inexpensive, and simple to use. As such,
they have the potential to be implemented as an alternative to fluorescent and
colorimetric detection methods utilized by many virological NAT assays.42-44

Four-Way Junction Biosensor
Our detection technique builds upon a universal four-way junction (4WJ) biosensor
described by Mills, D.M, et al.45 The 4WJ model utilizes a universal stem-loop-folded
DNA oligonucleotide (USL) immobilized on the surface of a gold electrode via a thiol
bond and backfilled with 6-mercaptohexanol (MCH) to prevent nonspecific
adsorption. Two adaptor strands, termed strand-m and strand-f, are introduced via a
hybridization solution to the electrode. The adaptor strands each have two binding
18

arms, one to bind to the USL and another to the target, separated by a triethylene
glycol spacer (Table 2). Additionally, strand-m contains a 10-thymidine linker
sequence covalently modified with a methylene blue (MeB) redox marker at the 5’end. In the presence of a target, the USL is unwound by the adaptor strands
hybridized to the abutting positions of the target, and a 4WJ structure is formed
between the USL, strand-m, strand-f, and the target (Figure 7). Without the target
present, the USL cannot be unwound, and the adaptor strands remain in solution
and are rinsed away.
The formation of the 4WJ structure places the MeB redox marker of strand-m near
the surface of the electrode allowing the electron transfer between the marker and
the electrode, originating an electrochemical signal to be measured via square-wave
voltammetry (SWV).

19

Figure 7. Schematic diagram of the 4WJ formation on the surface of a gold electrode.
Triethylene glycol spacers on both strand-m and strand-f are shown as dashed lines. The circle at the
end of strand-m represents the covalently-linked MeB.

We propose to use this design for our detection method with one modification: the
reversal of the described 4WJ platform. As our target is the amplicon tag, which is at
the 5’-end of the amplicon, using the 4WJ model described by Mills, D.M. et al.45
would project the remaining length of the amplicon towards the surface of the
electrode, which may cause nonspecific adsorption. Such an issue can be prevented
by reversing the directionality of the sensor by attaching the USL to the electrode at
its 3’-end and reversing the directionality of strand-m and strand-f (Figure 8).

20

A

B

Figure 8. Schematic diagram comparing the 4WJ when hybridizing the 5’-end of a target with the
stem-loop attached via the 5’-end (A) versus the 3’-end (B).
The red portion in each figure signifies the amplicon tag. Strand-m and strand-f are the blue and green
strands, respectively, with the dashed lines representing the triethylene glycol spacer. The MeB
modification on strand-m is not shown.
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MATERIALS & METHODS
Materials
Tris(2-carboxyethyl phosphine hydrochloride (TCEP), Trizma hydrochloride (TrisHCl), 6-Mercaptohexanol (MCH), and magnesium chloride (MgCl2) were purchased
from Sigma Aldrich (St. Louis, USA). TE buffer, NASBA Primers, strand-m, strandf, the blocking strand, and the HIV synthetic mimic were obtained from Integrated
DNA Technologies (Coralville, USA). The universal stem-loop (USL) was purchased
from Biosearch Technologies, Inc. (Petaluma, USA). All oligonucleotide sequences
used are shown in Table 1 and Table 2. NASBA kits (including NASBA buffer,
ribonucleotides, and enzyme cocktail) were purchased from Life Sciences Advanced
Technologies (St. Petersburg, USA). Ultrapure Agarose-1000 and SYBR Safe dye
were obtained from Thermo Fisher Scientific (Waltham, MA). Purified HIV-1 RNA
from the US1 isolate (GenBank: AY173952) was obtained from SeraCare Life
Sciences (Milford, MA). ssRNA ladder and RNA loading dye were obtained from New
England Biolabs (Ipswich, MA). NaCl, NaOH, and H2SO4 were purchased from Fisher
Scientific (Pittsburgh, USA). Gold disc electrodes (GDEs) were purchased from CH
Instruments (Austin, USA). Alumina slurry (1.0 µm, 0.3 µm, and 0.05 µm) was
obtained from Buehler (Lake Bluff, USA). All aqueous solutions were prepared with
deionized water (18.2 MΩ cm) using a Siemens PURELAB Ultra system (Lowell,
USA).
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Immobilization buffer (IB) was prepared as follows: 50 mM Tris-HCl and 250 mM
NaCl. The pH of IB was adjusted to pH 7.40 using a 1.0 M NaOH solution. The
hybridization buffer (HB) was prepared using 50 mM Tris-HCl, 100 mM NaCl, and
50 mM MgCl2. Likewise, the pH of HB was adjusted to pH 7.40 using 1.0 M NaOH.
NASBA Reaction
Viral RNA isolated from HIV-infected cells in fetal bovine serum (HIV-1 US1 isolate;
GenBank: AY173952) was used as the target for NASBA at varying concentrations.
The reaction was performed using the NASBA kit obtained from Life Sciences
Advanced Technologies (St. Petersburg, USA). NASBA samples were prepared by
combining 1X NASBA buffer (4 µL), NASBA nucleotide mix (2 µL), and primer mix
(2 µL to a final concentration of 250 nM of each primer). Samples contained varying
initial concentrations of HIV-1 US1 RNA (1 µL), while the no-target control (NTC)
contained 1 µL of nuclease-free water. The samples were incubated at 65 °C for 2
minutes, then at 41 °C for 10 minutes. 3 µL of the NASBA enzyme cocktail was then
added to each sample, and the samples continued to incubate at 41 °C for 90 minutes.
Following the completion of the reaction, samples were analyzed on a 2% agarose gel
containing SYBR Safe dye for band visualization. The gel images were analyzed using
a BioRad GelDoc XR+ with Image Lab software
Electrode Preparation
The GDEs were initially cleaned via immersion in piranha solution (1:3 ratio of 30%
H2O2 and conc. H2SO4) for 10 minutes. Next, the electrodes were manually polished
23

using a microcloth and alumina slurry (1.0 µm, then 0.5 µm, then 0.03 µm) and
sonicated in ethanol and deionized water to remove any residual alumina from the
electrode surface, for 2 minutes each. Lastly, the GDEs were activated via cyclic
voltammetry (CV) from 1.6 to -0.1 V at a scan rate of 100 mV•s-1 in 0.5 M H2SO4. The
electrochemically active area of each GDE was calculated using the CV
measurements as described by Carvalhal, R.F. et al.47 Following cleaning, the
electrodes were rinsed and dried with nitrogen.
To prepare the USL for immobilization onto the GDE, the disulfide bond was reduced
by adding 25 µL of 1.0 mM TCEP in IB to 10 µL of 1.0 µM USL in TE buffer. This
solution was then shaken for 1 hour at 25 °C. After shaking, the solution was further
diluted using 65 µL IB to a final concentration of 0.1 µM of USL. 15 µL of the USL
solution was then drop-casted onto the surface of each GDE and incubated for 30
minutes. The electrodes were then rinsed with IB and dried with nitrogen, and then
drop-casted with 15 µL of 2 mM MCH in IB and allowed to incubate for 30 minutes.
Electrochemical Measurements
Square-wave voltammetry (SWV) was performed using a CHI660D Electrochemical
Workstation. A three-electrode system was used where the modified GDE, a platinum
wire, and Ag/AgCl (1 M KCl) were used as working, counter, and reference electrodes,
respectively. SWV was performed in HB from 0.0 to -0.5 V, at a frequency of 100 Hz,
amplitude of 70 mV, and step potential of 3 mV. Before measurements were taken,
nitrogen was bubbled into the HB solution of the electrochemical cell for 15 minutes
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to remove dissolved oxygen. Measurements were taken, in triplicate, after
immobilization with MCH to obtain a baseline signal and after 4WJ formation at 25
°C.
4WJ Formation
The target (either the DNA target mimic or the NASBA product) was diluted to the
appropriate concentration in HB and then mixed with 0.25 µM strand-m, 0.50 µM
strand-f, and 0.50 µM blocking strand (if used). 15 µL of this solution was then
dropcasted onto the electrode surface and incubated for 90 minutes (except for
experiments whose purpose was to optimize the hybridization time). SWV was used
to obtain signal measurements, as described above. The signal expressed as the
current density (Δjp) after 4WJ formation minus the baseline signal was measured
for three replicate electrodes and then averaged.
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RESULTS & DISCUSSION
Sensor Design and Structure Prediction
The 4WJ biosensor was designed as described by Mills, D.M, et al.45 except that, in
this design, the USL is attached to the gold electrode via its 3’-end rather than the 5’end. The sensor strands—USL, strand-m, and strand-f—designed for this sensor are
shown in Table 1. Before physically testing our platform, we evaluated the predicted
4WJ structure formation with both the target and the primer (Figure 9) using
NUPACK software (nupack.org). For NUPACK analyses, the NASBA amplicon was
assumed to be DNA and not RNA as the software is unable to calculate the free energy
of formation of DNA:RNA hybrids. However, the structure prediction remains
consistent, regardless of whether the amplicon is DNA or RNA.
Both the NASBA amplicon and the RP were found to produce stable structures with
the 4WJ strands with free energies of -68.80 kcal/mol and -49.30 kcal/mol,
respectively. Further analysis showed that no structure formed between the USL,
strand-m, and strand-f in the absence of NASBA amplicon or RP.
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A

B

Figure 9. NUPACK predictions of 4WJ formation with the DNA mimic of the NASBA amplicon (A) or
RP (B) at 25 °C.
A) 4WJ formation between USL (yellow), strand-m (blue), strand-f (magenta) and DNA transcript of
NASBA amplicon (green) with a free energy of -68.60 kcal/mol. B) 4WJ formation between USL
(yellow), strand-m (blue), strand-f (magenta) and RP (purple) with a free energy of -49.30 kcal/mol.
Both analyses had strand concentrations of 0.1 µM USL, 0.25 µM strand-m, 0.5 µM strand-f, and 100
nM amplicon/RP.

Blocking Strand Design and Optimization
An issue that arises with our proposed assay is that the tag found in the antisense
amplicon will have the same sequence as the tag on RP (Table 1). Therefore,
nonspecific binding between RP and our sensor could produce false-positive signals
(Figure 9). To solve this problem, we introduce a blocking strand (Table 2), which is
complementary to the promoter found on RP but not in the amplicon, with 3-5
additional nucleotides upstream the strand-m binding site. We hypothesize that the
blocking strand would bind RP in a highly stable structure and prevent it from
hybridizing to our sensor while still allowing the target to bind, as the binding of the
blocking strand to the target is not as stable due to the lack of the 22-nt promoter
27

(Figure 10). Three of these strands were designed, block-3, block-4, and block-5 (Table
2), with 3, 4, and 5 nucleotides complementary to the strand-m binding portion of RP,
respectively.

Figure 10. Schematic of the mechanism of primer blocking.

Each blocking strand was then tested for its ability to block RP from binding while
still allowing the target to bind. This test was performed in two separate experiments;
the first being to test each blocking strand (0.5 µM) in the presence of 25 nM FP and
25 nM RP (to mimic the primer concentrations after dilution of the NASBA products),
along with a blank which contained no primers or blocking strands, and positive
control which contained 25 nM FP and 25 nM RP and no blocking strands (Figure
11A). Then, a similar experiment was conducted, except using 25 nM of the synthetic
DNA mimic, instead of primers, in the positive control and with the blocking strands
(Figure 11B).
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Figure 11. Performance of Blocking Strands in the Presence of Primer and Target.
A) Analysis of the blocking strand performance at 0.5 µM (Block-3, Block-4, and Block-5) in the
presence of 25 nM FP and 25 nM RP along with a positive (+) control containing 25 nM FP and 25
nM RP but no blocking strand and a blank containing no blocking strands or primers. B) Analysis of
the blocking strands at 0.5 µM (Block-3, Block-4, Block-5) in the presence of 25 nM of the synthetic
DNA mimic of the NASBA amplicon. The positive (+) control used contained 25 nM synthetic DNA
mimic but no blocking strands and the blank contained neither blocking strands nor the DNA mimic.
All hybridizing solutions in A and B contained 0.5 µM strand-f and 0.25 µM strand-m and were
incubated at 25 °C on the surface of the electrode for 90 minutes.

From the data shown in Figure 11A¸it can be seen that all blocking strands were able
to significantly reduce the signal produced by RP, with block-4 and block-5 reducing
the signal to background level. However, block-4 and block-5 seemed to interfere with
the binding of the synthetic DNA mimic to the sensor (Figure 11B), while block-3 did
not appear to reduce the signal produced by the DNA mimic. Therefore, while block3 was unable to reduce the signal produced by RP to the background level, it was still
selected for use in our assay as it allowed for a wider signal range.
To test if block-3 could reduce the RP signal even further, we varied the concentration
of RP (0.5 µM, 0.75 µM, 1.00 µM, and 1.50 µM) in the presence of 25 nM FP and 25
nM RP (Figure 12). The positive control and blank in this experiment were in the
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range of those shown in Figure 11A. We did not find a significant difference between
the varied concentrations of block-3 (Figure 12). Therefore, we elected to continue
using 0.5 µM as the concentration of block-3 for future experiments.
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6
5
4
3
2
1
0
Blank

0.5 mM

0.75 mM

1.0 mM (+) Control

Figure 12. Optimization of block-3 concentration.
Analysis of the performance of block-3 at varying concentrations (0.5, 0.75, and 1.0 µM) in addition to
a blank and positive control. All samples, except for the blank, contained 25 nM RP and 25 nM FP.
Neither the blank nor the positive (+) control contained any block-3. All samples contained 0.5 µM
strand-f and 0.25 µM strand-m and incubated at 25 °C for 90 minutes.

Sensor Characterization Using a Synthetic DNA Mimic

Optimization of 4WJ Hybridization Time
We first aimed to optimize the hybridization time for the 4WJ formation on the
surface of the electrode. To do so, we hybridized a blank negative control containing
only strand-m and strand-f for 90 minutes on the electrode, along with samples
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containing 50 nM HIV synthetic DNA mimic at 10, 30, 45, 50, and 90 minutes of
hybridization. We pre-emptively elected that the hybridization time should not
exceed 90 minutes to maintain the feasibility of assay implementation in the field. As
seen by the results in Figure 13, the signal produced by the biosensor continued to
increase significantly even after 60 minutes of hybridization. We, therefore, elected
to use a 90-minute hybridization time for all future experiments.
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Figure 13. Biosensor response to increased 4WJ hybridization time.
Inset curve: SWV response after hybridization of a blank (no target) at 90 minutes hybridization time
(black) or hybridization of 50 nM synthetic HIV DNA target at 10 (blue), 30 (red), 45 (orange), 60
(purple), and 90 (green) minutes of hybridization on the electrode surface at 25 °C. All samples
contained 0.25 µM strand-m and 0.5 µM strand-f.

After optimization of hybridization time, we then constructed a calibration curve of
the sensor response to increasing concentrations of the HIV-1 synthetic mimic (0, 1,
5, 15, and 25 nM) in the presence of 25 nM FP, 25 nM RP, and 0.5 µM block-3
incubated for 90 minutes at 25 °C (Figure 14). The results indicate that our sensor
has likely reached a saturation point even at the lowest concentrations tested when
the target is in the presence of primers (even when the blocking strand is present).
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An alternate hypothesis could be that the addition of primers and the blocking strand
combined with the target is causing steric hindrance and preventing the target from
hybridizing to the sensor.

Calibration Curve Using the Synthetic DNA Mimic
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Figure 14. Biosensor calibration curve for HIV-1 synthetic DNA mimic.
The concentrations of HIV-1 synthetic mimic were varied (0, 1, 5, 15, 25 nM) and hybridized for 90
minutes at 90 °C. Samples contained 25 nM FP, 25 nM RP, 0.5 µM block-3, 0.5 µM strand-f and 0.25
µM strand-m.

NASBA Amplification
Although discouraged by the calibration curve results with the synthetic DNA mimic,
we still aimed to construct a calibration curve for the products of NASBA
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amplification. We hypothesized that it might be possible to measure even a small
signal increase at the lower concentrations of the NASBA amplicon.
Gel electrophoresis of the NASBA products demonstrates successful amplification
and tagging of the HIV-1 US1 genome (Figure 15). The expected amplicon length with
the tag is approximately 153-nts, while the amplicon length without the tag is
approximately 125-nts.

Figure 15. Gel electrophoresis of NASBA products.
Gel electrophoresis of NASBA products on a 2% agarose gel. M: ssRNA nucleotide ladder with bands
corresponding to 100, 200, and 300 nts. NTC: no-target control. A-E: Initial concentration of RNA at
17.8, 1.78E2, 1.78E4, 1.78E6, and 1.78E8 copies/mL, respectively.

Unfortunately, the calibration curve for the NASBA products (Figure 16) indicated
similar results to those seen in Figure 14 with the synthetic DNA mimic. It appears
that even with the block-3 present, the RP is still at a high enough concentration to
produce a signal and cause saturation of our sensor.
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Figure 16. Biosensor response with the NASBA products.
Sensor response after using 5 µL of amplified samples to hybridize to the sensor for 90 minutes along
with 0.5 µM block-3, 0.5 µM strand-f, and 0.25 µM strand-m. The sample containing an initial RNA
concentration of 1.78E4 copies/mL was not tested due to a lack of available electrodes.
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FUTURE DIRECTIONS
Although there were some difficulties in fully developing the assay in this work, our
experiments demonstrate a promising opportunity for future exploration. First, a
calibration curve can possibly be produced by simply reducing the amount of NASBA
product used, reducing the concentration of primers in the samples, and eliminating
sensor saturation.
Should the primers still pose a problem even when using lower volumes of NASBA
product in the hybridization solution, several redesigns of the blocking can be
proposed to more effectively prevent primer hybridization to the sensor. One such
design would be to incorporate an internal triethylene glycol spacer to replace the
CTTCCC sequence found in the blocking strands. The complement of this sequence
is found in both RP and the NASBA amplicon and may be responsible for block-4 and
block-5, causing a reduced signal with the synthetic DNA mimic. By replacing this
sequence with a spacer, the binding of block-4 and block-5 with the target can be
destabilized, allowing us to use them for primer blocking since they proved more
effective than block-3 in preventing primer hybridization to the sensor. Another
design would be to add complementary G/C-rich sequences at either end of block-4
and block-5 and allowing a hairpin structure to form. Since the reverse primer has
the promoter, which contains 22-nts complementary to the blocking strands, the
flanking sequences can be designed to form a stable hairpin that would only unfold
when hybridizing to the promoter sequence. Finally, should neither redesign work,
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an alternative to primer blocking would be to treat the NASBA products with DNase
I, which would selectively degrade the DNA primers but leave the RNA amplicons
intact. However, this method is not ideal as it involves additional steps and dilution
of the NASBA products and would require the removal of the DNase I enzyme before
hybridization to the sensor since the USL and adaptor strands are DNA strands.
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CONCLUSION
In this work, we proposed a low-resource and sequence-independent assay for HIV
viral load quantitation. We utilized a modified NASBA technique to place a 22-nt tag
at the 5’-end of each RNA amplicon, which was subsequently hybridized to our 4WJ
biosensor for detection. In order to prevent the reverse primer, which contains the
same sequence as the amplicon which is interrogated by the sensor, from hybridizing
with our sensor, we designed a blocking strand that contains sequences
complementary to the T7 RNA Polymerase promoter, the additional purine stretch,
and three nucleotides from the amplicon tag.
While our initial experiments demonstrated successful NASBA amplification and
success in reducing the signal produced by the primer, later experiments
demonstrated that even with the blocking strand, our sensor reaches a saturation
point from the primers alone.
Therefore, while our proposed assay has produced promising results thus far, further
experimentation is required to identify the cause of sensor saturation. Once this is
accomplished, we may redesign and revisit the development of this assay, which
would be incredibly useful in low- and middle-income countries currently struggling
to implement quantitative HIV diagnostics due to a lack of funding, infrastructure,
and personnel.
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APPENDIX A:
NUCLEOTIDE SEQUENCES
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Table 1. NASBA and 4WJ Sequences
Name

Sequence (5' to 3')

RP

AATTCTAATACGACTCACTATAGGGAAGGATACTATATCAATAATGTAGACCCA
CTAACTTCTGTATGTCATTGACAGTC

FP

CATCAGAAAGAACCTCCATTCCTTTGGATG

NASBA Target

CATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCTGAT
AAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTC
AATGACATACAGAAGTTAGTGGG

NASBA

GGGAAGGAUACUAUAUCAAUAAUGUAGACCCACUAACUUCUGUAUGUC
AUUGACAGUCCAGCUGUCUUUUUCUGGCAGCACUAUAGGCUGUACUGU
CCAUUUAUCAGGAUGGAGUUCAUAACCCAUCCAAAGGAAUGGAGGUUC
UUUCUGAUG

Amplicon
Synthetic DNA

GGGAAGGATACTATATCAATAATGTAGACCCACTAACTTCTGTATGTCATT
GACAGTC

Mimic
USL

GCGCTAGATAACATACAATTGCGCTTTTTTTTTT-(CH2)6-S-S-(CH2)5CH2OH

Strand-m

MeB-TTTTTTTTTTCAATTGTAT/iSp9/ATAGTATC

Strand-f

TCTACATTATTGAT /iSp9/GTTATCTAG

The table above shows the nucleotide sequences for the NASBA reverse primer (RP), forward primer
(FP), NASBA target, product (i.e., the amplicon), the synthetic HIV DNA mimic, USL, strand-m, and
strand-f. Specific regions within the sequences are color-coded as follows: light blue represents the T7
RNA Polymerase promoter plus additional purines at the 3’-end of the blue portion, purple represents
the RP hybridizing region, orange represents binding between strand-m and the tag, pink represents
binding between strand-f and the tag, navy represents the FP hybridizing region, red represents
binding between the USL and strand-f, and green represents binding between USL and strand-m. The
underlined sequences are complementary to the non-underlined sequences of the same color.
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Table 2. Blocking Strand Sequences
Name

Sequence (5' to 3')

Block-3
Block-4
Block-5

ATCCTTCCCTATAGTGAGTCGTATTAGAATT
TATCCTTCCCTATAGTGAGTCGTATTAGAATT
GTATCCTTCCCTATAGTGAGTCGTATTAGAATT

The table above shows the nucleotide sequences for the three blocking strands (block-3, block-4, and
block-5) designed and tested for primer blocking in this work.
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